Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
Ninety-eight newly diagnosed cases of PML-RARalpha positive APL were treated with a regimen of single agent ATO. FLT3 activating mutations were seen in 33% and an additional cytogenetic finding was noted in 23.2%. FLT3 activating mutations were significantly associated with a bcr3 PML-RARalpha isoform (p=0.012) and a delay in achieving a molecular remission (p=0.022). Neither FLT3 activating mutations nor secondary cytogenetic changes had an impact on clinical outcome.
Mathews
Vikram
V
Department of Haematology, Christian Medical College, Vellore, 632004 India. vikram@cmcvellore.ac.in
Thomas
Maria
M
Srivastava
Vivi M
VM
George
Biju
B
Srivastava
Alok
A
Chandy
Mammen
M
D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D003582:Cytogenetics; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D009154:Mutation; D010087:Oxides / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
D001152:Arsenicals; D010087:Oxides; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D000077237:Arsenic Trioxide